ArticleTherapeutic advances in drug safety2026
A descriptive, retrospective analysis of the quality of spontaneous adverse event reporting to the Côte d'Ivoire Pharmaceutical and Regulatory Authority and its impact on the causality assessment.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Côte d'Ivoire, pharmacovigilance is not a routine activity in most healthcare facilities and many healthcare professionals have limited knowledge of pharmacovigilance methods. Objectives: This study aimed to evaluate the quality of adverse event (AE) reports submitted to the central Pharmacovigilance Unit in Côte d'Ivoire and to perform causality assessments (CAs) on each report. Design: This was a descriptive, retrospective analysis of AE reports notified between January 2019 and February 2020 by healthcare providers in Côte d'Ivoire. Methods: We assessed 141 verified reports of suspected adverse reactions to medicines, of which 118 reports were eligible for inclusion in the analysis of report quality using a modified Beckmann method. CAs were performed using the World Health Organization-Uppsala Monitoring Center (WHO-UMC) method and French CA method. Results: Of 118 AE reports, 28 (23.7%) had very good/good quality, 74 (62.7%) were average, 12 (10.2%) had poor quality, and 4 (3.4%) contained insufficient information for assessment. CAs could be performed for all reports except the four with insufficient information (three had no information on patient or suspected drug; all four had no information on the AE), although the reliability of the CA for poor quality reports was questionable. There was no significant difference in distribution of causality ratings calculated by the WHO-UMC method ( Conclusion: There is underreporting of AEs in Côte d'Ivoire and most AE reports had average quality. The reliability of the CA, irrespective of method used, was dependent on the quality of reporting. Further training and mentoring of healthcare providers are required to increase the number and completeness of AE reports submitted to the central Pharmacovigilance Unit, and thereby directly support more accurate CAs in Côte d'Ivoire.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.